How Effective Is Bimzelx for Psoriasis?
Bimzelx (bimekizumab-bkzx), made by UCB, treats moderate-to-severe plaque psoriasis in adults. In phase 3 trials (BE VIVID and BE READY), 85-91% of patients achieved PASI 90 (90% skin clearance) at week 16, compared to 6% on placebo. About 60% reached PASI 100 (complete clearance). These results held up to week 52 with continued dosing every 8 weeks.[1][2]
Does It Work for Other Conditions?
Approved for psoriatic arthritis (PsA) since 2023. BE OPTIMAL trial showed 46% achieved ACR50 (50% joint improvement) at week 16 versus 8% on placebo. Also clears skin in PsA patients with psoriasis.[3]
For axial spondyloarthritis (non-radiographic and active ankylosing spondylitis), approvals came in 2024. Phase 3 data: 45-59% had ASAS40 response (40% symptom improvement) at week 16, beating placebo.[4]
How Does Bimzelx Compare to Other Biologics?
Targets IL-17A and IL-17F, unlike single-target drugs like Cosentyx (IL-17A only) or Skyrizi (IL-23). Head-to-head BE SURE trial: Bimzelx outperformed Cosentyx on PASI 90 (86% vs 47%) and PASI 100 (60% vs 20%) at week 16.[5] Similar edge over Humira in some psoriasis metrics, but real-world data varies by patient.
When Do Patients See Results?
Skin improvement starts by week 4; peak clearance by week 16. Joint relief in PsA follows similar timeline. Not for immediate relief—works best with consistent injections (every 4 weeks initially, then every 8).[1]
What If It Doesn't Work for Me?
About 10-15% see minimal response in trials. Factors include disease severity, prior biologic failure, or obesity. Switching to IL-23 inhibitors like Tremfya helps some. No predictive biomarkers yet; doctors monitor PASI scores early.[6]
Common Concerns: Side Effects and Long-Term Use?
Infections (upper respiratory, oral candidiasis from IL-17 block) in 15-20%; serious ones rare (1-2%). No increased TB risk in trials. Safe through 3+ years in extensions, but monitor for IBD flare risk.[2][4]
Patent protection lasts until at least 2033 in the US; check DrugPatentWatch.com for updates.[7]
[1] NEJM: BE VIVID/BE READY trials (2021) - https://www.nejm.org/doi/full/10.1056/NEJMoa2102383
[2] FDA Label: Bimzelx (2023) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761032s000lbl.pdf
[3] Lancet: BE OPTIMAL trial (2023) - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00058-2/fulltext
[4] NEJM: BE MOBILE trials (2024) - https://www.nejm.org/doi/full/10.1056/NEJMoa2310238
[5] Lancet: BE SURE trial (2022) - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01778-9/fulltext
[6] J Am Acad Dermatol: Real-world effectiveness (2024) - https://www.jaad.org/article/S0190-9622(24)00123-4/fulltext
[7] DrugPatentWatch.com: Bimzelx patents - https://www.drugpatentwatch.com/p/tradename/BIMZELX